Viridian Therapeutics Inc (VRDN) - Total Liabilities
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has total liabilities worth $177.25 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VRDN cash flow conversion to assess how effectively this company generates cash.
Viridian Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check VRDN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Viridian Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viridian Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
China | CN¥3.93 Billion |
|
Suzhou New District Hi Tech Industrial Co Ltd
SHG:600736
|
China | CN¥59.74 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥1.23 Billion |
|
Net263 Ltd
SHE:002467
|
China | CN¥377.05 Million |
|
Suzhou Hailu Heavy Industry Co Ltd
SHE:002255
|
China | CN¥2.25 Billion |
|
Sigma Lithium Resources Corp
NASDAQ:SGML
|
USA | $259.05 Million |
|
Zhejiang Youpon Integrated Ceiling Co Ltd
SHE:002718
|
China | CN¥348.74 Million |
|
Proto Labs Inc
NYSE:PRLB
|
USA | $89.48 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Viridian Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VRDN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viridian Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $177.25 Million | +150.48% |
| 2024-12-31 | $70.76 Million | +46.20% |
| 2023-12-31 | $48.40 Million | +20.92% |
| 2022-12-31 | $40.03 Million | +150.28% |
| 2021-12-31 | $15.99 Million | +42.57% |
| 2020-12-31 | $11.22 Million | -22.68% |
| 2019-12-31 | $14.51 Million | -1.99% |
| 2018-12-31 | $14.80 Million | +5.96% |
| 2017-12-31 | $13.97 Million | +204.71% |
| 2016-12-31 | $4.58 Million | +83.99% |
| 2015-12-31 | $2.49 Million | +18.78% |
| 2014-12-31 | $2.10 Million | +27.45% |
| 2013-12-31 | $1.65 Million | -93.20% |
| 2012-12-31 | $24.22 Million | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more